Molecular response prediction in multimodality treatment for adenocarcinoma of the esophagus and esophagogastric junction.

摘要: Cancers arising from the esophagus are becoming more common in United States and Europe. In 2009, an estimate of 14,530 new cases will be diagnosed than 90% die their disease. Esophageal cancer is currently most rapidly increasing western world coinciding with a shift histological type primary tumor location. Despite recent improvements detection, surgical resection, (radio-) chemotherapy, overall survival (OS) esophageal remains relatively poor. It increasingly apparent that neoadjuvant chemoradiation followed by surgery may beneficial terms resectability OS compared to alone. Results clinical trials encouraging; however, they also demonstrated only patients major histopathological response (pCR) benefit therapy. addition, these therapies expensive prognoses who do not respond trimodality treatment strategies appear inferior had Accordingly, development validated predictive molecular markers helpful identifying EA likely respond, but critical selecting efficient means tailored, targeted, effective therapy profile both patient disease while minimizing avoiding life-threatening toxicities.